Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Beverly Teicher

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Anatomy

Cultured Tumor Cells

Physiology

Chemicals & Drugs

Disorders

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kurtzberg Leslie S; Roth Stephanie D; Bagley Rebecca G; Rouleau Cecile; Yao Min; Crawford Jennifer L; Krumbholz Roy D; Schmid Steven M; Teicher Beverly A
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Teicher Beverly A
Acute and chronic in vivo therapeutic resistance.
Bagley Rebecca G; Roth Stephanie; Kurtzberg Leslie S; Rouleau Cecile; Yao Min; Crawford Jennifer; Krumbholz Roy; Lovett Dennis; Schmid Steven; Teicher Beverly A
Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Beverly Teicher (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kurtzberg Leslie S; Roth Stephanie D; Bagley Rebecca G; Rouleau Cecile; Yao Min; Crawford Jennifer L; Krumbholz Roy D; Schmid Steven M; Teicher Beverly A
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Cancer chemotherapy and pharmacology 2009;64(5):1029-38.
2009: Teicher Beverly A
Acute and chronic in vivo therapeutic resistance.
Biochemical pharmacology 2009;77(11):1665-73.
2009: Bagley Rebecca G; Roth Stephanie; Kurtzberg Leslie S; Rouleau Cecile; Yao Min; Crawford Jennifer; Krumbholz Roy; Lovett Dennis; Schmid Steven; Teicher Beverly A
Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
International journal of oncology 2009;34(5):1329-40.
2009: Bagley Rebecca G; Weber William; Rouleau Cecile; Yao Min; Honma Nakayuki; Kataoka Shiro; Ishida Isao; Roberts Bruce L; Teicher Beverly A
Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers.
International journal of oncology 2009;34(3):619-27.
2009: Nacht Mariana; St Martin Thia B; Byrne Ann; Klinger Katherine W; Teicher Beverly A; Madden Stephen L; Jiang Yide
Netrin-4 regulates angiogenic responses and tumor cell growth.
Experimental cell research 2009;315(5):784-94.
2009: Teicher Beverly A
In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Toxicologic pathology 2009;37(1):114-22.
2008: Rouleau Cecile; Curiel Maritza; Weber William; Smale Robert; Kurtzberg Leslie; Mascarello James; Berger Carol; Wallar Gina; Bagley Rebecca; Honma Nakayuki; Hasegawa Kazumasa; Ishida Isao; Kataoka Shiro; Thurberg Beth L; Mehraein Khodadad; Horten Bruce; Miller Glenn; Teicher Beverly A
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7223-36.
2008: Bagley Rebecca G; Honma Nakayuki; Weber William; Boutin Paula; Rouleau Cecile; Shankara Srinivas; Kataoka Shiro; Ishida Isao; Roberts Bruce L; Teicher Beverly A
Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization.
Microvascular research 2008;76(3):180-8.
2008: Kurtzberg Leslie S; Battle Traci; Rouleau Cecile; Bagley Rebecca G; Agata Naoki; Yao Min; Schmid Steven; Roth Stephanie; Crawford Jennifer; Krumbholz Roy; Ewesuedo Reginald; Yu Xian-Jie; Wang Fei; Lavoie Edmond J; Teicher Beverly A
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Molecular cancer therapeutics 2008;7(10):3212-22.
2008: Bagley Rebecca G; Rouleau Cecile; St Martin Thia; Boutin Paula; Weber William; Ruzek Melanie; Honma Nakayuki; Nacht Mariana; Shankara Srinivas; Kataoka Shiro; Ishida Isao; Roberts Bruce L; Teicher Beverly A
Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248.
Molecular cancer therapeutics 2008;7(8):2536-46.
2008: Perry Kent; Wong Larry; Liu Victoria; Park Irwin; Zhang Qiang; Rejen Varun; Huang Xuemei; Smith Norm D; Jovanovic Borko; Lonning Scott; Teicher Beverly A; Lee Chung
Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.
Urology 2008;72(1):225-9.
2008: Rouleau Cecile; Menon Krishna; Boutin Paula; Guyre Cheryl; Yoshida Hitoshi; Kataoka Shiro; Perricone Michael; Shankara Srinivas; Frankel Arthur E; Duesbery Nicholas S; Vande Woude George; Biemann Hans-Peter; Teicher Beverly A
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution.
International journal of oncology 2008;32(4):739-48.
2008: Teicher Beverly A
Newer cytotoxic agents: attacking cancer broadly.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(6):1610-7.
2008: Teicher Beverly A
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
Biochemical pharmacology 2008;75(6):1262-71.
2004: Lobb Karen L; Hipskind Philip A; Aikins James A; Alvarez Enrique; Cheung Yiu-Yin; Considine Eileen L; De Dios Alfonso; Durst Gregory L; Ferritto Rafael; Grossman Cora Sue; Giera Deborah D; Hollister Beth A; Huang Zhongping; Iversen Philip W; Law Kevin L; Li Tiechao; Lin Ho-Shen; Lopez Beatriz; Lopez Jose E; Cabrejas Luisa M Martin; McCann Denis J; Molero Victoriano; Reilly John E; Richett Michael E; Shih Chuan; Teicher Beverly; Wikel James H; White Wesley T; Mader Mary M
Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents.
Journal of medicinal chemistry 2004;47(22):5367-80.
2004: Keyes Kristan A; Mann Larry; Sherman Michael; Galbreath Elizabeth; Schirtzinger Linda; Ballard Darryl; Chen Yun-Fei; Iversen Philip; Teicher Beverly A
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice.
Cancer chemotherapy and pharmacology 2004;53(2):133-40.
2003: Alvarez Enrique; Westmore Michael; Galvin Rachelle J Sells; Clapp Crystal L; Considine Eileen L; Smith Shawn J; Keyes Kristan; Iversen Philip W; Delafuente Dawn M; Sulaimon Shola; Zambrano Carmen; Ma Linda; Sato Masahiko; Martin T John; Teicher Beverly A; Galbreath Elizabeth J
Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5705-13.
2003: Zhu Guoxin; Conner Scott E; Zhou Xun; Shih Chuan; Li Tiechao; Anderson Bryan D; Brooks Harold B; Campbell Robert Morris; Considine Eileen; Dempsey Jack A; Faul Margaret M; Ogg Cathy; Patel Bharvin; Schultz Richard M; Spencer Charles D; Teicher Beverly; Watkins Scott A
Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Journal of medicinal chemistry 2003;46(11):2027-30.
2003: Keyes Kristan A; Mann Larry; Cox Karen; Treadway Patti; Iversen Philip; Chen Yun-Fei; Teicher Beverly A
Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
Cancer chemotherapy and pharmacology 2003;51(4):321-7.
2003: Zhu Guoxin; Conner Scott; Zhou Xun; Shih Chuan; Brooks Harold B; Considine Eileen; Dempsey Jack A; Ogg Cathy; Patel Bharvin; Schultz Richard M; Spencer Charles D; Teicher Beverly; Watkins Scott A
Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors.
Bioorganic & medicinal chemistry letters 2003;13(7):1231-5.
2003: Keyes Kristan A; Mann Larry; Teicher Beverly; Alvarez Enrique
Site-dependent angiogenic cytokine production in human tumor xenografts.
Cytokine 2003;21(2):98-104.
2002: Keyes Kristan; Cox Karen; Treadway Patti; Mann Larry; Shih Chuan; Faul Margaret M; Teicher Beverly A
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
Cancer research 2002;62(19):5597-602.
2002: Teicher Beverly A; Menon Krishna; Alvarez Enrique; Shih Chuan; Faul Margaret M
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
Investigational new drugs 2002;20(3):241-51.
2002: Teicher Beverly A; Alvarez Enrique; Menon Krishna; Esterman Michail A; Considine Eileen; Shih Chuan; Faul Margaret M
Antiangiogenic effects of a protein kinase Cbeta-selective small molecule.
Cancer chemotherapy and pharmacology 2002;49(1):69-77.
2001: Teicher B A; Menon K; Alvarez E; Galbreath E; Shih C; Faul M M
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts.
Cancer chemotherapy and pharmacology 2001;48(6):473-80.
2001: Teicher B A; Menon K; Alvarez E; Galbreath E; Shih C; Faul M M
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
Anticancer research 2001;21(5):3175-84.
2001: Asea A; Mallick R; Lechpammer S; Ara G; Teicher B A; Fiorentino S; Stevenson M A; Calderwood S K
Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2001;17(5):401-14.
2001: Shih C; Teicher B A
Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
Current pharmaceutical design 2001;7(13):1259-76.
2001: Asea A; Ara G; Teicher B A; Stevenson M A; Calderwood S K
Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2001;17(4):347-56.
2001: Teicher B A; Menon K; Alvarez E; Liu P; Shih C; Faul M M
Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.
In vivo (Athens, Greece) 2001;15(3):185-93.
2001: Teicher B A; Menon K; Alvarez E; Galbreath E; Shih C; Faul M
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):634-40.
2001: Lu K; Dempsey J; Schultz R M; Shih C; Teicher B A
Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells.
Cancer chemotherapy and pharmacology 2001;47(2):170-8.
2000: Teicher B A; Forler P; Menon K; Phares V; Amsrud T; Shih C
Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts.
In vivo (Athens, Greece) 2000;14(4):471-80.
2000: Teicher B A; Chen V; Shih C; Menon K; Forler P A; Phares V G; Amsrud T
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):1016-23.
2000: Liu P; Menon K; Alvarez E; Lu K; Teicher B A
Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo.
International journal of oncology 2000;16(3):599-610.
2000: Lu K; Shih C; Teicher B A
Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.
Cancer chemotherapy and pharmacology 2000;46(4):293-304.
2000: Menon K; Alvarez E; Forler P; Phares V; Amsrud T; Shih C; Al-Awar R; Teicher B A
Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Cancer chemotherapy and pharmacology 2000;46(2):142-9.
2000: Frei E; Ara G; Teicher B; Bunnell C; Richardson P; Wheeler C; Tew K; Elias A
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Cancer chemotherapy and pharmacology 2000;45(3):239-46.
1999: Teicher B A; Ara G; Herbst R; Palombella V J; Adams J
The proteasome inhibitor PS-341 in cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2638-45.
1999: Teicher B A; Alvarez E; Liu P; Lu K; Menon K; Dempsey J; Schultz R M
MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
Seminars in oncology 1999;26(2 Suppl 6):55-62.
1999: Teicher B A; Alvarez E; Mendelsohn L G; Ara G; Menon K; Ways D K
Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy.
Advances in enzyme regulation 1999;39():313-27.
1998: Teicher B A; Ara G; Chen Y N; Recht A; Coleman C N
Interaction of tomudex with radiation in vitro and in vivo.
International journal of oncology 1998;13(3):437-42.
1998: Teicher B A; Williams J I; Takeuchi H; Ara G; Herbst R S; Buxton D
Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Anticancer research 1998;18(4A):2567-73.
1998: Elias A D; Wheeler C; Ayash L J; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman K H; Teicher B A; Frei E
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1443-9.
1998: Ara G; Gravelin L M; Kaddurah-Daouk R; Teicher B A
Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism.
In vivo (Athens, Greece) 1998;12(2):223-31.
1998: Teicher B A; Ara G; Keyes S R; Herbst R S; Frei E
Acute in vivo resistance in high-dose therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):483-91.
1998: Takeuchi H; Ara G; Sausville E A; Teicher B
Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma.
Cancer chemotherapy and pharmacology 1998;42(6):491-6.
1998: Eder J P; Chan V; Wong J; Wong Y W; Ara G; Northey D; Rizvi N; Teicher B A
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
Cancer chemotherapy and pharmacology 1998;42(4):327-35.
1998: Teicher B A; Wong J S; Takeuchi H; Gravelin L M; Ara G; Buxton D
Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo.
Cancer chemotherapy and pharmacology 1998;42(1):24-30.
1998: Teicher B A; Ara G; Buxton D; Leonard J; Schaub R G
Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma.
Radiation oncology investigations 1998;6(2):71-80.
1998: Herbst R S; Takeuchi H; Teicher B A
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Cancer chemotherapy and pharmacology 1998;41(6):497-504.
1997: Teicher B A; Ikebe M; Ara G; Keyes S R; Herbst R S
Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
In vivo (Athens, Greece) 1997;11(6):463-72.
1997: Teicher B A; Kakeji Y; Ara G; Herbst R S; Northey D
Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
In vivo (Athens, Greece) 1997;11(6):453-61.
1997: Teicher B A; Ara G; Buxton D; Leonard J; Schaub R G
Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1661-7.
1997: Teicher B A; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
In vivo (Athens, Greece) 1997;11(4):301-11.
1997: Kakeji Y; Maehara Y; Ikebe M; Teicher B A
Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma.
International journal of radiation oncology, biology, physics 1997;37(5):1115-23.
1997: Teicher B A; Maehara Y; Kakeji Y; Ara G; Keyes S R; Wong J; Herbst R
Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin.
International journal of cancer. Journal international du cancer 1997;71(1):49-58.
1997: Kakeji Y; Teicher B A
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Investigational new drugs 1997;15(1):39-48.
1997: Holden S A; Emi Y; Kakeji Y; Northey D; Teicher B A
Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
Cancer chemotherapy and pharmacology 1997;40(1):87-93.
1996: Teicher B A; Emi Y; Kakeji Y; Northey D
TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy.
European journal of cancer (Oxford, England : 1990) 1996;32A(14):2461-6.
1996: Ayash L J; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher B A; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(11):2984-92.
1996: Teicher B A; Chen Y N; Ara G; Emi Y; Kakeji Y; Maehara Y; Keyes S; Northey D
Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma.
International journal of cancer. Journal international du cancer 1996;67(6):864-70.
1996: Teicher B A; Northey D; Yuan J; Frei E
High-dose therapy/stem cell support: comparison of mice and humans.
International journal of cancer. Journal international du cancer 1996;65(5):695-9.
1996: Ara G; Teicher B A
Cyclooxygenase and lipoxygenase inhibitors in cancer therapy.
Prostaglandins, leukotrienes, and essential fatty acids 1996;54(1):3-16.
1996: Teicher B A; Ara G; Menon K; Schaub R G
In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment.
International journal of cancer. Journal international du cancer 1996;65(1):80-4.
1996: Wong J S; Ara G; Keyes S R; Herbst R; Coleman C N; Teicher B A
Lisofylline as a modifier of radiation therapy.
Oncology research 1996;8(12):513-8.
1996: Teicher B A; Holden S A; Goff D A; Wright J E; Tretyakov O; Ayash L J
Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Cancer chemotherapy and pharmacology 1996;38(6):553-60.
1996: Teicher B A; Holden S A; Ara G; Korbut T; Menon K
Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.
Cancer chemotherapy and pharmacology 1996;38(2):169-77.
1996: Teicher B A; Holden S A; Ara G; Chen G
Transforming growth factor-beta in in vivo resistance.
Cancer chemotherapy and pharmacology 1996;37(6):601-9.
1996: Zhou G H; Teicher B A; Frei E
Postlabeling detection of DNA adducts of antitumor alkylating agents.
Cancer chemotherapy and pharmacology 1996;38(1):71-80.
1995: Eder J P; Chan V T; Ng S W; Rizvi N A; Zacharoulis S; Teicher B A; Schnipper L E
DNA topoisomerase II alpha expression is associated with alkylating agent resistance.
Cancer research 1995;55(24):6109-16.
1995: Teicher B A; Holden S A; Ara G; Menon K
Whole-body hyperthermia and lonidamine as adjuvant therapy to treatment with cisplatin with or without local radiation in mouse bearing the Lewis lung carcinoma.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1995;11(5):637-45.
1995: Kusumoto T; Holden S A; Ara G; Teicher B A
Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1995;11(4):575-86.
1995: Teicher B A; Holden S A; Ara G; Dupuis N P; Goff D
Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing.
The cancer journal from Scientific American 1995;1(1):43-8.
1995: Teicher B A; Holden S A; Ara G; Dupuis N P; Liu F; Yuan J; Ikebe M; Kakeji Y
Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy.
International journal of cancer. Journal international du cancer 1995;61(5):732-7.
1995: Teicher B A
Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia.
Hematology/oncology clinics of North America 1995;9(2):475-506.
1995: Teicher B A; Dupuis N P; Emi Y; Ikebe M; Kakeji Y; Menon K
Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma.
In vivo (Athens, Greece) 1995;9(1):11-8.
1995: Teicher B A; Dupuis N P; Robinson M F; Emi Y; Goff D A
Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
Oncology research 1995;7(5):237-43.
1995: Teicher B A; Holden S A; Dupuis N P; Kakeji Y; Ikebe M; Emi Y; Goff D
Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Breast cancer research and treatment 1995;36(2):227-36.
1995: Chatterjee D; Liu C J; Northey D; Teicher B A
Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors.
Cancer chemotherapy and pharmacology 1995;35(5):423-31.
1995: Teicher B A; Menon K; Northey D; Liu J; Kufe D W; Kaddurah-Daouk R
Cyclocreatine in cancer chemotherapy.
Cancer chemotherapy and pharmacology 1995;35(5):411-6.
1995: Holden S A; Teicher B A; Robinson M F; Northey D; Rosowsky A
Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Cancer chemotherapy and pharmacology 1995;36(2):165-71.
1995: Brooks S E; Korbut T T; Dupuis N P; Holden S A; Teicher B A
Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
Cancer chemotherapy and pharmacology 1995;36(5):431-8.
1995: Robinson M F; Dupuis N P; Kusumoto T; Liu F; Menon K; Teicher B A
Increased tumor oxygenation and radiation sensitivity in two rat tumors by a hemoglobin-based, oxygen-carrying preparation.
Artificial cells, blood substitutes, and immobilization biotechnology 1995;23(3):431-8.
1995: Dupuis N P; Kusumoto T; Robinson M F; Liu F; Menon K; Teicher B A
Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing.
Artificial cells, blood substitutes, and immobilization biotechnology 1995;23(3):423-9.
1995: Teicher B A
An overview on oxygen carriers in cancer therapy.
Artificial cells, blood substitutes, and immobilization biotechnology 1995;23(3):395-405.
1994: Holden S A; Teicher B A; Frei E
Long-term persistence and cytokinetics of human tumor cells in vitro following high-dose alkylating agent exposure.
Cancer letters 1994;87(2):211-22.
1994: Ara G; Coleman C N; Teicher B A
SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells.
Cancer letters 1994;85(2):195-203.
1994: Teicher B A; Holden S A; Liu C J; Ara G; Herman T S
Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo.
Cancer letters 1994;82(1):17-25.
1994: Teicher B A; Holden S A; Ara G; Sotomayor E A; Huang Z D; Chen Y N; Brem H
Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.
International journal of cancer. Journal international du cancer 1994;57(6):920-5.
1994: Ara G; Kusumoto T; Korbut T T; Cullere-Luengo F; Teicher B A
cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
Cancer research 1994;54(6):1497-502.
1994: Teicher B A; Dupuis N P; Robinson M F; Kusumoto T; Liu M; Menon K
Reduced oxygenation in a rat mammary carcinoma post-radiation and reoxygenation with a perflubron emulsion/carbogen breathing.
In vivo (Athens, Greece) 1994;8(1):125-31.
1994: Teicher B A; Korbut T T; Menon K; Holden S A; Ara G
Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Cancer chemotherapy and pharmacology 1994;33(6):515-22.
1994: Teicher B A; Schwartz J L; Holden S A; Ara G; Northey D
In vivo modulation of several anticancer agents by beta-carotene.
Cancer chemotherapy and pharmacology 1994;34(3):235-41.
1994: Teicher B A; Holden S A; Dupuis N P; Kusomoto T; Liu M; Liu F; Menon K
Oxygenation of the rat 9L gliosarcoma and the rat 13672 mammary carcinoma with various doses of a hemoglobin solution.
Artificial cells, blood substitutes, and immobilization biotechnology 1994;22(3):827-33.
1994: Teicher B A; Sotomayor E A; Dupuis N P; Kusumoto T; Menon K
Reduced oxygenation in a rat mammary carcinoma after chemo- or radiation therapy and reoxygenation with perflubron emulsion/carbogen breathing.
Journal of cancer research and clinical oncology 1994;120(10):593-8.
1994: Teicher B A; Holden S A; Chen Y N; Ara G; Korbut T T; Northey D
CAI: effects on cytotoxic therapies in vitro and in vivo.
Cancer chemotherapy and pharmacology 1994;34(6):515-21.
1994: Teicher B A; Schwartz G N; Dupuis N P; Kusomoto T; Liu M; Liu F; Northey D
Oxygenation of human tumor xenografts in nude mice by a perfluorochemical emulsion and carbogen breathing.
Artificial cells, blood substitutes, and immobilization biotechnology 1994;22(4):1369-75.
1994: Teicher B A
Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy.
Artificial cells, blood substitutes, and immobilization biotechnology 1994;22(4):1109-20.
1994: Teicher B A
Lonidamine: in vitro/in vivo correlations.
European journal of cancer (Oxford, England : 1990) 1994;30A(10):1411-3.
1993: Teicher B A; Holden S A; Ara G; Northey D
Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
Anticancer research 1993;13(6A):2101-6.
1993: Teicher B A; Liu S D; Liu J T; Holden S A; Herman T S
A carbonic anhydrase inhibitor as a potential modulator of cancer therapies.
Anticancer research 1993;13(5A):1549-56.
1993: Eder J P; Chan V T; Niemierko E; Teicher B A; Schnipper L E
Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells.
The Journal of biological chemistry 1993;268(19):13844-9.
1993: Huang Z D; Chen Y N; Menon K; Teicher B A
Synthesis and evaluation of the antitumor activity of 4,5-diamino-substituted 1,2-benzoquinones.
Journal of medicinal chemistry 1993;36(13):1797-801.
1993: Teicher B A; Holden S A; Northey D; Dewhirst M W; Herman T S
Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside.
International journal of radiation oncology, biology, physics 1993;26(1):103-9.
1993: Boscia R E; Korbut T; Holden S A; Ara G; Teicher B A
Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
International journal of cancer. Journal international du cancer 1993;53(1):118-23.
1993: Teicher B A; Holden S A; Khandakar V; Herman T S
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Journal of cancer research and clinical oncology 1993;119(11):645-51.
1993: Teicher B A; Chatterjee D; Liu J T; Holden S A; Ara G
Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.
Cancer chemotherapy and pharmacology 1993;32(4):315-9.
1993: Teicher B A; Schwartz G N; Alvarez Sotomayor E; Robinson M F; Dupuis N P; Menon K
Oxygenation of tumors by a hemoglobin solution.
Journal of cancer research and clinical oncology 1993;120(1-2):85-90.
1993: Teicher B A; Sotomayor E A; Huang Z D; Ara G; Holden S; Khandekar V; Chen Y N
beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Cancer chemotherapy and pharmacology 1993;33(3):229-38.
1993: Teicher B A; Holden S A; Menon K; Hopkins R E; Gawryl M S
Effect of hemoglobin solution on the response of intracranial and subcutaneous 9L tumors to antitumor alkylating agents.
Cancer chemotherapy and pharmacology 1993;33(1):57-62.
1993: Frei E; Holden S A; Gonin R; Waxman D J; Teicher B A
Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.
Cancer chemotherapy and pharmacology 1993;33(2):113-22.
1993: Schwartz G N; Teicher B A; Eder J P; Korbut T; Holden S A; Ara G; Herman T S
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Cancer chemotherapy and pharmacology 1993;32(6):455-62.
1992: Teicher B A; Sotomayor E A; Huang Z D
Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Cancer research 1992;52(23):6702-4.
1992: Teicher B A; Herman T S; Menon K; Korbut T T
Whole-body hyperthermia as an adjuvant to treatment with platinum complexes with or without etanidazole in mice bearing the Lewis lung carcinoma or the FSaLL fibrosarcoma.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1992;8(6):783-94.
1992: Herman T S; Teicher B A; Varshney A; Khandekar V; Brann T
Effect of hypoxia and acidosis on the cytotoxicity of mitoxantrone, bisantrene and amsacrine and their platinum complexes at normal and hyperthermic temperatures.
Anticancer research 1992;12(3):827-36.
1992: Tanaka J; Holden S A; Herman T S; Teicher B A
Response of subpopulations of the FSall C fibrosarcoma to low dose x-rays and various potential enhancing agents.
Anticancer research 1992;12(3):1029-33.
1992: Ara G; Varshney A; Ha C S; Oseroff A R; Herman T S; Teicher B A
Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light.
Photochemistry and photobiology 1992;55(4):561-7.
1992: Holden S A; Teicher B A; Ara G; Herman T S; Coleman C N
Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Journal of the National Cancer Institute 1992;84(3):187-93.
1992: Antman K; Ayash L; Elias A; Wheeler C; Hunt M; Eder J P; Teicher B A; Critchlow J; Bibbo J; Schnipper L E
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(1):102-10.
1992: Teicher B A; Herman T S; Hopkins R E; Menon K
Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
Journal of cancer research and clinical oncology 1992;118(2):123-8.
1992: Teicher B A; Holden S A; Ara G; Ha C S; Herman T S; Northey D
A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
Journal of cancer research and clinical oncology 1992;118(7):509-14.
1992: Epelbaum R; Teicher B A; Holden S A; Ara G; Varshney A; Herman T S
Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
European journal of cancer (Oxford, England : 1990) 1992;28A(4-5):794-800.
1992: Sotomayor E A; Teicher B A; Schwartz G N; Holden S A; Menon K; Herman T S; Frei E
Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Cancer chemotherapy and pharmacology 1992;30(5):377-84.
1992: Teicher B A; Herman T S; Menon K
Enhancement of fractionated radiation therapy by an experimental concentrated perflubron emulsion (Oxygent) in the Lewis lung carcinoma.
Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology 1992;20(2-4):899-902.
1992: Holden S A; Teicher B A; Ha C; Ara G; Herman T S
Enhancement by perflusion emulsion (Oxygent) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents.
Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology 1992;20(2-4):895-8.
1992: Teicher B A
Use of perfluorochemical emulsions in cancer therapy.
Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology 1992;20(2-4):875-82.
1992: Teicher B A; Holden S A; Ara G; Herman T S; Hopkins R E; Menon K
Effect of a bovine hemoglobin preparation (SBHS) on the response of two murine solid tumors to radiation therapy or chemotherapeutic alkylating agents.
Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology 1992;20(2-4):657-60.
1991: Ayash L; Korbut T; Herman T S; Teicher B A
Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Cancer letters 1991;61(1):7-14.
1991: Teicher B A; Holden S A; Rudolph M B; Sotomayor E A; Herman T S
Effect of environmental conditions (pH, oxygenation and temperature) on the cytotoxicity of flavone acetic acid and its dimethylaminoethyl ester.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1991;7(6):905-15.
1991: Herman T S; Teicher B A; Holden S A
Addition of mitomycin C to cis-diamminedichloroplatinum(II)/hyperthermia/radiation therapy in the FSaIIC fibrosarcoma.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1991;7(6):893-903.
1991: Teicher B A; Varshney A; Khandekar V; Herman T S
Effect of hypoxia and acidosis on the cytotoxicity of six metal(ligand)4(rhodamine-123)2 complexes at normal and hyperthermic temperatures.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1991;7(6):857-68.
1991: Teicher B A; Herman T S; Hopkins R E; Menon K
Effect of oxygen level on the enhancement of tumor response to radiation by perfluorochemical emulsions or a bovine hemoglobin preparation.
International journal of radiation oncology, biology, physics 1991;21(4):969-74.
1991: Teicher B A; Pfeffer M R; Alvarez Sotomayor E; Herman T S
Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1991;7(5):773-84.
1991: Teicher B A; Herman T S; Holden S A; Rudolph M B
Effect of oxygenation, pH and hyperthermia on RSU-1069 in vitro and in vivo with radiation in the FSaIIC murine fibrosarcoma.
Cancer letters 1991;59(2):109-17.
1991: Teicher B A; Holden S A; Herman T S; Epelbaum R; Pardee A B; Dezube B
Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Anticancer research 1991;11(4):1555-60.
1991: Tanaka J; Teicher B A; Herman T S; Holden S A; Dezube B; Frei E
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
International journal of cancer. Journal international du cancer 1991;48(4):631-7.
1991: Holden S A; Teicher B A; Herman T S
Effect of environmental conditions (pH, oxygenation, and temperature) on misonidazole cytotoxicity and radiosensitization in vitro and in vivo in FSaIIC fibrosarcoma.
International journal of radiation oncology, biology, physics 1991;20(5):1031-8.
1991: Teicher B A; Holden S A; Herman T S; Frei E
Modulation of alkylating agents by lonidamine in vivo.
Seminars in oncology 1991;18(2 Suppl 4):7-10.
1991: Teicher B A; Herman T S; Holden S A
Effect of pH, oxygenation, and temperature on the cytotoxicity and radiosensitization by etanidazole.
International journal of radiation oncology, biology, physics 1991;20(4):723-31.
1991: Teicher B A; Herman T S; Holden S A; Epelbaum R; Liu S D; Frei E
Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Cancer research 1991;51(3):780-4.
1991: Teicher B A; Herman T S; Tanaka J; Eder J P; Holden S A; Bubley G; Coleman C N; Frei E
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Cancer research 1991;51(4):1086-91.
1991: Teicher B A; Holden S A; Herman T S; Sotomayor E A; Khandekar V; Rosbe K W; Brann T W; Korbut T T; Frei E
Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
International journal of cancer. Journal international du cancer 1991;47(2):252-60.
1991: Teicher B A; Herman T S; Tanaka J; Dezube B; Pardee A; Frei E
Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Cancer chemotherapy and pharmacology 1991;28(1):45-50.
1991: Teicher B A; Herman T S; Shulman L; Bubley G; Coleman C N; Frei E
Combination of etanidazole with cyclophosphamide and platinum complexes.
Cancer chemotherapy and pharmacology 1991;28(3):153-8.
1990: Pfeffer M R; Teicher B A; Holden S A; al-Achi A; Herman T S
The interaction of cisplatin plus etoposide with radiation +/- hyperthermia.
International journal of radiation oncology, biology, physics 1990;19(6):1439-47.
1990: Teicher B A; Abrams M J; Rosbe K W; Herman T S
Cytotoxicity, radiosensitization, antitumor activity, and interaction with hyperthermia of a Co(III) mustard complex.
Cancer research 1990;50(21):6971-5.
1990: Teicher B A; Herman T S; Jones S M
Influence of scheduling, dose, and volume of administration of a perfluorochemical emulsion on tumor response to radiation therapy.
International journal of radiation oncology, biology, physics 1990;19(4):945-51.
1990: Herman T S; Teicher B A; Pfeffer M R; Khandekar V; Chapnick R M; Kalick G S; Rabow A
Effect of acidic pH on radiosensitization of FSaIIC cells in vitro by misonidazole, etanidazole, or cis-diamminedichloroplatinum (II).
Radiation research 1990;124(1):28-33.
1990: Herman T S; Teicher B A; Coleman C N
Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
Cancer research 1990;50(16):5055-9.
1990: Teicher B A; Stemwedel J; Herman T S; Ghoshal P K; Rosowsky A
1,2-dithiol-3-thione and dithioester analogues: potential radioprotectors.
British journal of cancer 1990;62(1):17-22.
1990: Herman T S; Teicher B A; Pfeffer M R; Khandekar V S; Korbut T T
Interaction with hyperthermia of tetrachloroplatinum(II)(Nile blue)2 and tetrachloroplatinum(II)(neutral red)2 in EMT6 murine cells and the murine FSaIIC fibrosarcoma.
Cancer research 1990;50(13):3826-31.
1990: Eder J P; Elias A; Shea T C; Schryber S M; Teicher B A; Hunt M; Burke J; Siegel R; Schnipper L E; Frei E
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1239-45.
1990: Teicher B A; Holden S A; al-Achi A; Herman T S
Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
Cancer research 1990;50(11):3339-44.
1990: Herman T S; Teicher B A; Pfeffer M R; Khandekar V S
Interaction with hyperthermia of platinum complexes of triaminotriphenylmethane dyes.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 1990;6(3):629-39.
1990: Herman T S; Teicher B A; Holden S A; Pfeffer M R; Jones S M
Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma.
Cancer research 1990;50(9):2734-40.
1990: Holden S A; Herman T S; Teicher B A
Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1990;18(1):59-70.
1990: Teicher B A; Herman T S; Holden S A; Wang Y Y; Pfeffer M R; Crawford J W; Frei E
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.
Science (New York, N.Y.) 1990;247(4949 Pt 1):1457-61.
1990: Teicher B A; Herman T S; Kaufmann M E
Cytotoxicity, radiosensitization, and DNA interaction of platinum complexes of thiazin and xanthene dyes.
Radiation research 1990;121(2):187-95.
1990: Antman K; Eder J P; Elias A; Ayash L; Shea T C; Weissman L; Critchlow J; Schryber S M; Begg C; Teicher B A
High-dose thiotepa alone and in combination regimens with bone marrow support.
Seminars in oncology 1990;17(1 Suppl 3):33-8.
1990: Teicher B A; Holden S A; Eder J P; Herman T S; Antman K H; Frei E
Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
Seminars in oncology 1990;17(1 Suppl 3):18-32.
1990: Herman T S; Teicher B A; Holden S A
Trimodality therapy (drug/hyperthermia/radiation) with BCNU or mitomycin C.
International journal of radiation oncology, biology, physics 1990;18(2):375-82.
1990: Herman T S; Teicher B A; Pfeffer M R; Khandekar V S; Alvarez Sotomayor E
Interaction of platinum complexes of thiazin and xanthene dyes with hyperthermia.
Cancer chemotherapy and pharmacology 1990;26(2):127-34.
1990: Eder J P; Teicher B A; Holden S A; Senator L; Cathcart K N; Schnipper L E
Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline.
Cancer chemotherapy and pharmacology 1990;26(6):423-8.
1989: Teicher B A; Herman T S; Pfeffer M R; Alvarez Sotomayor E; Khandekar V S
Interaction of PtCl4(Fast Black)2 with hyperthermia.
Cancer research 1989;49(22):6208-13.
1989: Wang Y Y; Teicher B A; Shea T C; Holden S A; Rosbe K W; al-Achi A; Henner W D
Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Cancer research 1989;49(22):6185-92.
1989: Teicher B A; Holden S A; Eder J P; Brann T W; Jones S M; Frei E
Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Cancer research 1989;49(21):5994-8.
1989: Teicher B A; Herman T S; Kaufmann M E
DNA interaction, cytotoxicity, and radiosensitization with PtCl4(Nile Blue)2 and PtCl4(Neutral Red)2.
Radiation research 1989;120(1):129-39.
1989: Teicher B A; Herman T S; Kaufmann M
Platinum complexes of triaminotriphenylmethanes: interaction with DNA and radiosensitization.
Cancer letters 1989;47(3):217-28.
1989: Teicher B A; Waxman D J; Holden S A; Wang Y Y; Clarke L; Alvarez Sotomayor E; Jones S M; Frei E
Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
Cancer research 1989;49(18):4996-5001.
1989: Teicher B A; Herman T S; Kaufmann M E
Interaction of platinum(II) tetrachlorodianion (Fast Black)2 with superhelical DNA and with radiation in vitro and in vivo.
Radiation research 1989;119(1):134-44.
1989: Herman T S; Teicher B A; Holden S A; Collins L S
Interaction of hyperthermia and radiation in murine cells: hypoxia and acidosis in vitro, tumor subpopulations in vivo.
Cancer research 1989;49(12):3338-43.
1989: Teicher B A; Herman T S; Holden S A; Jones S M
Addition of misonidazole, etanidazole, or hyperthermia to treatment with fluosol-DA/carbogen/radiation.
Journal of the National Cancer Institute 1989;81(12):929-34.
1989: Teicher B A; Herman T S; Jones S M
Optimization of perfluorochemical levels with radiation therapy in mice.
Cancer research 1989;49(10):2693-7.
1989: Wang Y; Herman T S; Teicher B A
Platinum-dye complexes inhibit repair of potentially lethal damage following bleomycin treatment.
British journal of cancer 1989;59(5):722-6.
1989: Frei E; Antman K; Teicher B; Eder P; Schnipper L
Bone marrow autotransplantation for solid tumors--prospects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):515-26.
1989: Eder J P; Teicher B A; Holden S A; Cathcart K N; Schnipper L E; Frei E
Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Cancer research 1989;49(3):595-8.
1989: Herman T S; Teicher B A; Chan V; Collins L S; Abrams M J
Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes.
International journal of radiation oncology, biology, physics 1989;16(2):443-9.
1989: Rosbe K W; Brann T W; Holden S A; Teicher B A; Frei E
Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Cancer chemotherapy and pharmacology 1989;25(1):32-6.
1989: Teicher B A; Holden S A; Jones S M; Eder J P; Herman T S
Influence of scheduling on two-drug combinations of alkylating agents in vivo.
Cancer chemotherapy and pharmacology 1989;25(3):161-6.
1988: Chan V; Elliott K E; Herman T S; Teicher B A
Alphoid DNA nucleotide sequences from two human cell lines and the corresponding cis-diamminedichloroplatinum(II)-resistant sublines.
Cancer letters 1988;43(3):219-25.
1988: Frei E; Teicher B A; Holden S A; Cathcart K N; Wang Y Y
Preclinical studies and clinical correlation of the effect of alkylating dose.
Cancer research 1988;48(22):6417-23.
1988: Teicher B A; Herman T S; Rose C M
Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
International journal of radiation oncology, biology, physics 1988;15(5):1187-92.
1988: Teicher B A; Herman T S; Holden S A
Combined modality therapy with bleomycin, hyperthermia, and radiation.
Cancer research 1988;48(22):6291-7.
1988: Eder J P; Antman K; Elias A; Shea T C; Teicher B; Henner W D; Schryber S M; Holden S; Finberg R; Chritchlow J
Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors.
Journal of the National Cancer Institute 1988;80(15):1221-6.
1988: Teicher B A; Crawford J M; Holden S A; Lin Y; Cathcart K N; Luchette C A; Flatow J
Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide.
Cancer 1988;62(7):1275-81.
1988: Herman T S; Teicher B A; Cathcart K N; Kaufmann M E; Lee J B; Lee M H
Effect of hyperthermia on cis-diamminedichloroplatinum(II) (rhodamine 123)2[tetrachloroplatinum(II)] in a human squamous cell carcinoma line and a cis-diamminedichloroplatinum(II)-resistant subline.
Cancer research 1988;48(18):5101-5.
1988: Teicher B A; Holden S A; Crawford J M
Effects of Fluosol-DA and oxygen breathing on adriamycin antitumor activity and cardiac toxicity in mice.
Cancer 1988;61(11):2196-201.
1988: Teicher B A; Holden S A; Cathcart K N; Herman T S
Effect of various oxygenation conditions and fluosol-DA on cytotoxicity and antitumor activity of bleomycin in mice.
Journal of the National Cancer Institute 1988;80(8):599-603.
1988: Herman T S; Teicher B A
Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma.
Cancer research 1988;48(10):2693-7.
1988: Teicher B A; Holden S A; Cucchi C A; Cathcart K N; Korbut T T; Flatow J L; Frei E
Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
Cancer research 1988;48(1):94-100.
1988: Teicher B A; Frei E
Development of alkylating agent-resistant human tumor cell lines.
Cancer chemotherapy and pharmacology 1988;21(4):292-8.
1988: Teicher B A; Jacobs J L; Kelley M J
The influence of Fluosol-DA on the occurrence of lung metastases in Lewis lung carcinoma and B16 melanoma.
Invasion & metastasis 1988;8(1):45-56.
1988: Teicher B A; Herman T S; Holden S A; Cathcart K N
The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
Cancer chemotherapy and pharmacology 1988;21(4):286-91.
1988: Teicher B A; Bernal S D; Holden S A; Cathcart K N
Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
Cancer chemotherapy and pharmacology 1988;21(4):281-5.
1988: Teicher B A; McIntosh-Lowe N L; Rose C M
Effect of various oxygenation conditions and fluosol-DA on cancer chemotherapeutic agents.
Biomaterials, artificial cells, and artificial organs 1988;16(1-3):533-46.
1987: Rosowsky A; Wright J E; Cucchi C A; Flatow J L; Trites D H; Teicher B A; Frei E
Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II).
Cancer research 1987;47(22):5913-8.
1987: Teicher B A; Crawford J M; Holden S A; Cathcart K N
Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
Cancer research 1987;47(19):5036-41.
1987: Teicher B A; Holden S A; Cathcart K N
Efficacy of Pt(Rh-123)2 as a radiosensitizer with fractionated X rays.
International journal of radiation oncology, biology, physics 1987;13(8):1217-24.
1987: Eder J P; Teicher B A; Holden S A; Cathcart K N; Schnipper L E
Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.
The Journal of clinical investigation 1987;79(5):1524-8.
1987: Teicher B A; Holden S A; Kelley M J; Shea T C; Cucchi C A; Rosowsky A; Henner W D; Frei E
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Cancer research 1987;47(2):388-93.
1986: Teicher B A; Cucchi C A; Lee J B; Flatow J L; Rosowsky A; Frei E
Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Cancer research 1986;46(9):4379-83.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Beverly Teicher

Research Profile (preview)

Living Beings

Anatomy

Physiology

Chemicals & Drugs

Disorders

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Beverly Teicher (preview)

All Publications